Wilson Sonsini Advises NTx on $47.5 Million Series B
Wilson Sonsini Advises NTx on $47.5 Million Series B
Client Highlights11/17/23
Life Sciences
Our Industry Coverage
With one of the largest life sciences practices in the U.S., Wilson Sonsini’s industry legacy dates to the formative years of biotech and medical device. Working closely with scientists and entrepreneurs who grew their companies into thriving businesses, we have worked alongside to support their endeavors from whiteboard to clinical trial and beyond.
Industry Highlights
Celebrating our founders’ successes
2013
NanoString Files IPO Worth $54 Million
Molecular Diagnostics2020
Lumos Pharma Sets Sights on SPAC
Drug Discovery2020
Oric Pharmaceuticals IPO Raises $120 Million
Drug Discovery2020
Applied Molecular Transport Closes IPO at $154 Million
Pharmaceuticals2020
ALX Oncology Prices IPO at $161 Million
Immuno-Oncology2020
HintMD is Acquired by Revance Therapeutics
Mobile Healthcare Platform2020
Athira Pharma Closes $204 Million IPO
Drug Discovery2020
PMV Pharmaceuticals Joins Nasdaq with $211 Million IPO
Drug Discovery2020
Artelo Biosciences Announces $6.6 Million Public Offering
Cannabinoid-Based Therapies2020
Seer IPO Raises $175 Million in Nasdaq Debut
Decision / Risk AnalysisAttorneys
focused
on this
industry
recent news
we want to share
with you
Wilson Sonsini Advises Aqtual on Series A Funding
Wilson Sonsini Advises Aqtual on Series A Funding
Client Highlights10/31/23
Wilson Sonsini Advises Novo Holdings on MapLight Therapeutics’ $225 Million Series C
Wilson Sonsini Advises Novo Holdings on MapLight Therapeutics’ $225 Million Series C
Client Highlights10/31/23
Wilson Sonsini Advises DermBiont on $35.2 Million Series B Financing
Wilson Sonsini Advises DermBiont on $35.2 Million Series B Financing
Client Highlights10/25/23